Synthaverse S.A. (SVE.WA)
PLN 4.28
(7.0%)
PLN 4.28
(7.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 265.9 Million PLN | 63.03% |
| 2022 | 163.09 Million PLN | 39.61% |
| 2021 | 116.82 Million PLN | 36.06% |
| 2020 | 85.86 Million PLN | 5.86% |
| 2019 | 81.11 Million PLN | -5.96% |
| 2018 | 86.25 Million PLN | -28.73% |
| 2017 | 121.02 Million PLN | 7.43% |
| 2016 | 112.65 Million PLN | -32.2% |
| 2015 | 166.16 Million PLN | 47.93% |
| 2014 | 112.32 Million PLN | 14.96% |
| 2013 | 97.7 Million PLN | 3.81% |
| 2012 | 94.12 Million PLN | -11.41% |
| 2011 | 106.25 Million PLN | 44.63% |
| 2010 | 73.46 Million PLN | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 291.71 Million PLN | 9.71% |
| 2024 Q2 | 293.22 Million PLN | 0.52% |
| 2023 Q2 | 193.94 Million PLN | 11.73% |
| 2023 Q4 | 265.9 Million PLN | 17.19% |
| 2023 FY | 265.9 Million PLN | 63.03% |
| 2023 Q3 | 226.9 Million PLN | 16.99% |
| 2023 Q1 | 173.58 Million PLN | 6.43% |
| 2022 Q3 | 127.33 Million PLN | 3.71% |
| 2022 FY | 163.09 Million PLN | 39.61% |
| 2022 Q2 | 122.78 Million PLN | 0.87% |
| 2022 Q4 | 163.09 Million PLN | 28.09% |
| 2022 Q1 | 121.71 Million PLN | 4.19% |
| 2021 Q3 | 103.75 Million PLN | 0.0% |
| 2021 Q4 | 116.82 Million PLN | 12.6% |
| 2021 FY | 116.82 Million PLN | 36.06% |
| 2021 Q1 | 85.05 Million PLN | -0.94% |
| 2020 Q2 | 81.5 Million PLN | 4.39% |
| 2020 Q4 | 85.86 Million PLN | 6.21% |
| 2020 FY | 85.86 Million PLN | 5.86% |
| 2020 Q3 | 80.83 Million PLN | -0.81% |
| 2020 Q1 | 78.07 Million PLN | -3.74% |
| 2019 Q3 | 83.37 Million PLN | -4.42% |
| 2019 Q4 | 81.11 Million PLN | -2.72% |
| 2019 Q2 | 87.23 Million PLN | 0.43% |
| 2019 Q1 | 86.85 Million PLN | 0.7% |
| 2019 FY | 81.11 Million PLN | -5.96% |
| 2018 Q3 | 114.83 Million PLN | -5.79% |
| 2018 Q1 | 121.71 Million PLN | 0.57% |
| 2018 Q4 | 86.25 Million PLN | -24.88% |
| 2018 FY | 86.25 Million PLN | -28.73% |
| 2018 Q2 | 121.88 Million PLN | 0.14% |
| 2017 Q4 | 121.02 Million PLN | -10.44% |
| 2017 FY | 121.02 Million PLN | 7.43% |
| 2017 Q2 | 140.25 Million PLN | -7.89% |
| 2017 Q3 | 135.12 Million PLN | -3.65% |
| 2017 Q1 | 152.27 Million PLN | 35.16% |
| 2016 Q4 | 112.65 Million PLN | -16.67% |
| 2016 FY | 112.65 Million PLN | -32.2% |
| 2016 Q2 | 139.01 Million PLN | -14.59% |
| 2016 Q3 | 135.19 Million PLN | -2.75% |
| 2016 Q1 | 162.76 Million PLN | -2.05% |
| 2015 Q4 | 166.16 Million PLN | 5.69% |
| 2015 FY | 166.16 Million PLN | 47.93% |
| 2015 Q3 | 157.22 Million PLN | 5.16% |
| 2015 Q2 | 149.51 Million PLN | 14.72% |
| 2015 Q1 | 130.32 Million PLN | 16.02% |
| 2014 FY | 112.32 Million PLN | 14.96% |
| 2014 Q1 | 100.57 Million PLN | 2.93% |
| 2014 Q2 | 112.4 Million PLN | 11.77% |
| 2014 Q4 | 112.32 Million PLN | -9.74% |
| 2014 Q3 | 124.44 Million PLN | 10.72% |
| 2013 Q3 | 97.76 Million PLN | 2.61% |
| 2013 Q4 | 97.7 Million PLN | -0.05% |
| 2013 Q2 | 95.27 Million PLN | -0.05% |
| 2013 Q1 | 95.32 Million PLN | 1.27% |
| 2013 FY | 97.7 Million PLN | 3.81% |
| 2012 Q4 | 94.12 Million PLN | 0.0% |
| 2012 FY | 94.12 Million PLN | -11.41% |
| 2011 FY | 106.25 Million PLN | 44.63% |
| 2010 FY | 73.46 Million PLN | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bioceltix S.A. | 12.73 Million PLN | -1987.922% |
| BIOTON S.A. | 822.22 Million PLN | 67.661% |
| Captor Therapeutics Spolka Akcyjna | 97.29 Million PLN | -173.298% |
| Mabion S.A. | 208.25 Million PLN | -27.682% |
| Molecure S.A. | 168.57 Million PLN | -57.733% |
| NanoGroup S.A. | 8.63 Million PLN | -2980.581% |
| Pharmena S.A. | 24.13 Million PLN | -1001.869% |
| Poltreg S.A. | 127.09 Million PLN | -109.211% |
| Pure Biologics Spólka Akcyjna | 22.73 Million PLN | -1069.421% |
| Ryvu Therapeutics S.A. | 403.2 Million PLN | 34.052% |
| Urteste S.A. | 29.59 Million PLN | -798.382% |